Bellicum Logo.jpg
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
October 31, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
October 30, 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT -   HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM),...
Bellicum Logo.jpg
CORRECTING and REPLACING - Bellicum Pharmaceuticals, Inc.
August 16, 2019 10:52 ET | Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
August 16, 2019 08:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and Encourages Bellicum Investors to Contact the Firm
May 31, 2019 19:00 ET | Bragar Eagel & Squire
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM). ...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and Encourages Bellicum Investors to Contact the Firm
May 31, 2019 19:00 ET | Bragar Eagel & Squire
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM). ...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 16:14 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
May 15, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
February 12, 2018 15:17 ET | Federman & Sherwood
OKLAHOMA CITY, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on February 6, 2018, a class action lawsuit was filed in the United States District Court for the Southern...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET | Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...